Aurimed Pharma

AurimMed Pharma is an applied-science, development-stage pharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for central nervous system (CNS) disorders. Utilizing its proprietary Privileged Structure Platform (PSP), which leverages a curated knowledge-base of clinically successful chemical scaffolds, the company designs compounds with optimized ADMET profiles and reduced toxicity. AurimMed's pipeline includes its lead candidate, AMP-X-0079, a novel small-molecule anticonvulsant being developed for drug-resistant epilepsy and status epilepticus. Additionally, the company is advancing preclinical programs for spinal muscular atrophy (SMA), Parkinson's disease, and neuropathic pain.